Short answer
Inhibikase Therapeutics, Inc. (IKT) filed its Q1 2026 10-Q quarterly report on May 12, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $0 with net income of −$16M.
Q1 2026 key financials · XBRL
- Revenue
- $0
- Net income
- −$16M
- −19.8% YoY
- EPS (diluted)
- −$0.10
- +33.3% YoY
Source: XBRL data from the Inhibikase Therapeutics, Inc. (IKT) Q1 2026 10-Q on SEC EDGAR. USD.
Inhibikase Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material risk-factor changes from the December 31, 2025 Annual Report
- Carried-forward risks include clinical-development uncertainty for investigational therapies
- Continued financing risk typical of development-stage biotechnology operations
- Ongoing regulatory and compliance risk surrounding clinical trials and product approvals
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Inhibikase Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.